Sara Nazha

A cost-effectiveness analysis of bladder management strategies in neurogenic lower urinary tract dysfunction after spinal cord injury: A publicly funded health care perspective

Samer Shamout, Sara Nazha, Alice Dragomir, Richard Baverstock et autres

ca (code pays fourni par la source)

Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers

Alice Dragomir, Sara Nazha, Simon Tanguay, Rodney H. Breau et autres

ca (code pays fourni par la source)

Patient Healthcare Trajectory and its Impact on the Cost-Effectiveness of Fracture Liaison Services

Andréa Senay, Julio Fernandes, J. Delisle, Suzanne N. Morin et autres

This study aimed to assess the cost-utility of a Fracture Liaison Service (FLS) with a systematic follow-up according to patients' follow-up compliance trajectories. The Lucky Bone™ FLS is a prospective cohort study conducted on women and men (≥40 years) with fragility fractures. …

ca (code pays fourni par la source)

Author response for "Patient Healthcare Trajectory and its Impact on the Cost‐Effectiveness of Fracture Liaison Services"

Andréa Senay, Julio Fernandes, J. Delisle, Suzanne N. Morin et autres

Author response for "Patient Healthcare Trajectory and its Impact on the Cost‐Effectiveness of Fracture Liaison Services"

Andréa Senay, Julio Fernandes, J. Delisle, Suzanne N. Morin et autres

Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: The Canadian Kidney Cancer information system experience

Alice Dragomir, Sara Nazha, Lori Wood, Ricardo Rendon et autres

ca (code pays fourni par la source)

PD45-12 ECONOMIC EVALUATION OF RENAL CELL CARCINOMA (RCC) IN CANADA USING REAL-WORLD EVIDENCE; A HEALTHCARE SYSTEM PERSPECTIVE

Alice Dragomir, Sara Nazha, I Yanev, Simon Tanguay

You have accessJournal of UrologyKidney Cancer: Epidemiology & Evaluation/Staging/Surveillance II (PD45)1 Apr 2020PD45-12 ECONOMIC EVALUATION OF RENAL CELL CARCINOMA (RCC) IN CANADA USING REAL-WORLD EVIDENCE; A HEALTHCARE SYSTEM PERSPECTIVE Alice Dragomir*, Sara Nazha, Ivan Yanev, and Simon Tanguay Alice Dragomir*Alice Dragomir* More …

PD51-12 COST-EFFECTIVENESS OF IMMUNOTHERAPIES IN METASTATIC BLADDER CANCER: A CANADIAN HEALTHCARE PERSPECTIVE

Côme Tholomier, Sara Nazha, Alice Dragomir, Wassim Kassouf

INTRODUCTION AND OBJECTIVE: The development of immunotherapies (IOs) for the treatment of bladder cancer in first and second-line increased the economic burden of this disease. We aimed to use an economic model to compare the cost-effectiveness when IOs are included in the …

One-Year Outcomes with Once or Twice Daily Enoxaparin

Adi J. Klil‐Drori, Sara Nazha, Marlène Gharib, Sylvie Perreault et autres

Background: Enoxaparin given once daily (QD) for thrombotic disorders is less burdensome than twice-daily (BID) dosing. However, long-term outcomes when enoxaparin given as QD monotherapy are unknown. Methods: We did a population-based cohort study. New users of enoxaparin alone (2005-2014) were identified …

ca (code pays fourni par la source)

ON4 THE ECONOMIC BURDEN OF RENAL CELL CARCINOMA (RCC) IN CANADA USING REAL-WORLD EVIDENCE; A SOCIETAL PERSPECTIVE.

Sara Nazha, I Yanev, Floman Le, Simon Tanguay et autres

ca (code pays fourni par la source)

PCN72 COST OF MANAGING METASTATIC BLADDER CANCER WITH THE INTRODUCTION OF IMMUNOTHERAPIES FROM A CANADIAN HEALTHCARE PERSPECTIVE

Sara Nazha, Côme Tholomier, Wassim Kassouf, Alice Dragomir

ca (code pays fourni par la source)

The clinical and economic burden of metastatic renal cell carcinoma in Canada in real-world setting

Sara Nazha

AbstractAim: The management of metastatic renal cell carcinoma (mRCC) has changed significantly in the past decade with the scientific advancement in the field of pharmacotherapy, the search for optimal timing of surgery and different ablation methods. In parallel, the economic burden of …